Concord Biotech Limited (CONCORDBIO) — Cash Flow Reinvestment Rate
Concord Biotech Limited (CONCORDBIO) has a Cash Flow Reinvestment Rate of 0.45x as of March 2025, reinvesting Rs1.11 Billion (capex Rs1.11 Billion ) from operating cash flow of Rs2.47 Billion. Explore Concord Biotech Limited (CONCORDBIO) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Concord Biotech Limited Cash Flow Reinvestment Rate (2020–2025)
Historical reinvestment intensity for Concord Biotech Limited across 6 annual periods. Also explore Concord Biotech Limited asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Concord Biotech Limited (2020–2025)
Year-by-year capital reinvestment analysis for Concord Biotech Limited. For live market cap and broader valuation context, see CONCORDBIO stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (INR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.45x | Rs1.11 Billion | Rs2.47 Billion | Rs1.11 Billion | ▲ +39.2% |
| 2024 | 0.32x | Rs856.88 Million | Rs2.65 Billion | Rs856.88 Million | ▼ -45.3% |
| 2023 | 0.59x | Rs1.45 Billion | Rs2.46 Billion | Rs1.45 Billion | ▼ -21.3% |
| 2022 | 0.75x | Rs1.56 Billion | Rs2.07 Billion | Rs1.56 Billion | ▼ -38.8% |
| 2021 | 1.22x | Rs2.04 Billion | Rs1.67 Billion | Rs2.04 Billion | ▲ +21.9% |
| 2020 | 1.00x | Rs1.55 Billion | Rs1.55 Billion | Rs1.55 Billion | — |